What is the difference between gender dysphoria and gender incongruence?

Gender dysphoria (DSM-5-TR) and gender incongruence (ICD-11) both describe a mismatch between a person's experienced gender identity and their sex assigned at birth, but they differ in framing. DSM-5-TR retains a distress criterion: gender dysphoria requires clinically significant distress or functional impairment as part of the diagnosis. ICD-11's 'gender incongruence' (HA60) does not require distress — it recognises that gender incongruence itself is not inherently pathological, and that distress arises mainly from social stigma and minority stress rather than from gender diversity per se. ICD-11 places gender incongruence in the 'Conditions related to sexual health' chapter, not the mental disorders chapter. Many people with a trans or non-binary gender identity do not meet DSM criteria for gender dysphoria, particularly after social transition.

Can a GP prescribe gender-affirming hormones, or do I need to see a specialist?

In Australia, GPs can prescribe gender-affirming hormone therapy for adults under an informed consent model, consistent with AusPATH 2022 Standards of Care. This means the GP documents the patient's understanding of risks, benefits, alternatives, and the irreversible effects of hormones, and prescribes without requiring a psychiatric gatekeeping letter. Many GPs, particularly in cities, now offer this. For adolescents, the picture is more complex: puberty blockers and cross-sex hormones in adolescents are prescribed by paediatricians or paediatric endocrinologists in consultation with a multidisciplinary team; the Re Kelvin 2017 Family Court ruling means court authorisation is no longer required when both parents and the clinical team agree the treatment is in the young person's best interest.

Are conversion practices legal in Australia?

No — conversion practices targeting sexual orientation or gender identity are banned by law in Victoria, Queensland, the Australian Capital Territory, and New South Wales. The specific legislation and definitions vary between jurisdictions. Practices range from formal 'therapy' programmes to informal pressure from family members or religious leaders. These laws apply to health practitioners, religious practitioners, and parents. The Australian Psychological Society and all major Australian health professional bodies have condemned conversion practices as harmful and ineffective. If a patient discloses they have been subjected to conversion practices, document this as a safeguarding and mental health concern and refer to LGBTQ+ affirming mental health services.

What mental health risks do transgender people face and how does GP care help?

Research — including the Trans Pathways 2017 study of 859 young trans Australians — documents very high rates of psychological distress, with 79.7% reporting self-harm and 48.1% attempting suicide in their lifetime. These rates are overwhelmingly driven by minority stress: discrimination, family rejection, bullying, and lack of affirming care — not by gender identity itself. Gender-affirming care, including access to hormone therapy and social affirmation, is associated with substantial reductions in depression, anxiety, and suicidality. A GP's role in creating an affirming clinical environment — using correct names and pronouns, maintaining confidentiality, conducting sensitive physical assessments — is itself a health intervention. Refer to LGBTQ+ affirming mental health support when psychological distress is present.

What is the evidence around puberty blockers for adolescents in Australia?

Puberty blockers (gonadotropin-releasing hormone analogues such as leuprorelin) are used in Australia to pause endogenous puberty in gender-diverse adolescents during a period of exploration and multidisciplinary assessment. AusPATH 2022 supports their use in appropriate adolescents. The evidence base was reviewed in the UK Cass Report (2024), which raised concerns about the quality of existing studies and prompted NHS England to restrict puberty blocker prescribing outside clinical trials. This finding has been contested by WPATH, EPATH, and many professional bodies who argue the Cass Review applied different evidentiary standards to gender medicine than to comparable paediatric care. Australian guidelines have not adopted the Cass restrictions; access is through paediatric multidisciplinary teams at specialist centres including the Royal Children's Hospital Melbourne and Sydney Children's Hospital. Families and young people should discuss the current evidence and uncertainties openly with their treating team.

Gender dysphoria

Gender dysphoria: GP role in affirmative care and Australian pathways

By Dr HB Lo, FACRRM Reviewed 6 August 2026 10 min read

Gender dysphoria (DSM-5-TR F64.0) is the clinically significant distress arising from incongruence between a person's experienced gender identity and their sex assigned at birth. ICD-11 reclassified the equivalent concept as "gender incongruence" (HA60) outside the mental disorders chapter, reflecting consensus that gender diversity is not inherently pathological.

Australian GPs initiate gender-affirming hormone therapy under an informed consent model and coordinate multidisciplinary referral for adolescents. Conversion practices targeting gender identity are banned in Victoria, Queensland, the ACT, and New South Wales.

AusPATH 2022 and WPATH SOC8 are the principal clinical frameworks.

Gender dysphoria describes clinically significant distress arising from incongruence between a person’s experienced gender identity and their sex assigned at birth. For GPs, the clinical imperative is to provide affirming, person-centred care that reduces minority stress — the primary driver of the elevated mental health burden in trans and gender diverse populations — while safely initiating and monitoring gender-affirming medical treatments where indicated.

A. Core clinical — the AU general-practice framework

Diagnostic frameworks

Two classification systems are in use simultaneously:

DSM-5-TR (2022): Gender dysphoria requires a marked incongruence between experienced and assigned gender, lasting at least 6 months, associated with clinically significant distress or functional impairment. Adult/adolescent criteria (F64.0) include at least two of: incongruence between gender identity and primary/secondary sex characteristics; strong desire to be rid of or prevent the development of primary/secondary sex characteristics; strong desire for the sex characteristics of the other gender; strong desire to be of another gender; strong desire to be treated as another gender; and strong conviction of feeling like another gender. Childhood gender dysphoria (F64.8) uses age-appropriate criteria focusing on persistent cross-gender identification.

ICD-11 HA60 (WHO 2022): “Gender incongruence of adolescence or adulthood” requires a marked and persistent incongruence between a person’s experienced gender and their assigned sex. Crucially, ICD-11 removes the distress criterion and relocates the diagnosis to “Conditions related to sexual health” — not the mental disorders chapter. This change reflects the consensus that gender diversity is not a disorder. The ICD-11 framework is increasingly adopted by Australian services to avoid stigmatising framing.

Building an affirming clinical environment

An affirming consultation is itself therapeutic. Practical steps:

Ask patients their preferred name, pronouns, and how they wish to describe their gender — then use these consistently in conversation and clinical notes
Update medical records to reflect preferred name and gender markers
Consider the physical examination environment — offer a chaperone, explain each examination step, and defer any examination that is not clinically essential that day if the patient is distressed
Maintain absolute confidentiality about gender identity, particularly for adolescents whose family situation may be unsafe

History-taking

Key areas:

Duration and experience of gender incongruence: onset, how it has evolved, and current living situation (social transition, name/pronoun use)
Current mental health: depression, anxiety, self-harm, and suicidality — document and treat, not as a prerequisite for affirming care, but as concurrent clinical problems
Social support: family acceptance, peer relationships, school or workplace environment
Previous gender-affirming care: hormones, surgery, private or public services
Substance use, medical comorbidities, and medications that interact with hormone therapy
Reproductive goals: oocyte, sperm, or embryo preservation before initiating gonadal-suppressive treatment

Contraindications to hormone therapy (relative)

There are few absolute contraindications. Relative contraindications to gender-affirming hormone therapy that require specialist co-management include: active hormone-sensitive malignancy, decompensated liver disease, severe cardiovascular disease (particularly for oestradiol in trans women with high VTE risk), or inability to provide informed consent.

B. Evidence basis — gender-affirming care and outcomes

Mental health burden and the minority stress model

The Trans Pathways study (Strauss et al., 2017), conducted at Telethon Kids Institute, surveyed 859 trans young Australians (aged 14–25) and remains the most cited Australian dataset. Key findings:

79.7% reported lifetime self-harm
48.1% reported a lifetime suicide attempt
Access to gender-affirming care, family support, and social affirmation were the strongest protective factors

These figures represent minority stress outcomes — the consequence of discrimination, invalidation, family rejection, and lack of affirming healthcare — not outcomes inherent to gender diversity. Longitudinal cohort studies consistently show that gender-affirming hormone therapy and social support are associated with clinically significant reductions in depression, anxiety, and suicidality at 1–2 year follow-up.

Regret and detransition rates

Contrary to common misconceptions, regret rates among adults who have undergone gender-affirming medical treatment are low. Systematic reviews consistently estimate social and medical detransition rates of less than 1–2% of those who medically transition, with most detransition attributable to external factors (family pressure, discrimination, financial barriers) rather than changed gender identity. Studies that find higher apparent detransition rates typically include social-only transition or apply alternative definitions. Australian clinicians should inform patients of these rates as part of informed consent discussions.

Neurodevelopmental overlap

Warrier et al. (Nature Communications 2020) found elevated rates of autistic traits and autism diagnoses in transgender and gender diverse individuals across multiple large datasets (community + clinical), consistent with earlier clinical observations. This co-occurrence has clinical implications: assessment and communication may need to be adapted; however, autism is not a contraindication to gender-affirming care and should not be used as a rationale to defer or withhold it. Specialist consultation with autism-experienced gender clinicians is appropriate when assessment complexity warrants it.

Puberty blockers — current evidence and the Cass Review

Gonadotropin-releasing hormone analogues (GnRH-a, puberty blockers) are used in adolescents with gender dysphoria to pause endogenous pubertal development during multidisciplinary assessment. Published evidence on long-term outcomes is limited (small samples, short follow-up, no randomised controlled trials), as acknowledged by all clinical guidelines.

The UK Cass Review (2024) — an independent review commissioned by NHS England — concluded that the evidence base for puberty blockers in gender-dysphoric adolescents was insufficient to support use outside research settings, leading to restrictions in the UK National Health Service. WPATH, EPATH, and several major endocrinology and paediatric societies have contested the review’s methodology and conclusions, arguing that the evidentiary standards applied were not those used for other paediatric interventions. AusPATH 2022 continues to support puberty blocker use in appropriate adolescents via specialist multidisciplinary teams. GPs should communicate this ongoing evidence uncertainty to families while directing them to specialist centres.

C. Legal framework — Australian-specific

Conversion practices legislation

Practices aimed at suppressing or changing a person’s gender identity or sexual orientation (“conversion practices” or “conversion therapy”) are prohibited by law in:

Victoria: Change or Suppression (Conversion) Practices Prohibition Act 2021 — applies to health practitioners, religious practitioners, and parents; carries criminal penalties
Queensland: Health Legislation Amendment Act 2023 and Criminal Code Amendment (Conversion Practices Prohibition) Act 2024
Australian Capital Territory: Sexuality and Gender Identity Conversion Practices Act 2020
New South Wales: Change or Suppression (Conversion) Practices Prohibition Act 2024
Other jurisdictions are at various stages of similar legislation

GPs should be aware of these obligations. Referral to a practitioner who performs conversion practices may expose the GP to liability.

Adolescents — Family Court and Re Kelvin

Before the 2017 Family Court decision Re Kelvin, parents of adolescents with gender dysphoria were required to apply to the Family Court to authorise Stage 2 treatment (cross-sex hormone therapy). The Re Kelvin ruling confirmed that court authorisation is not required when:

The young person is Gillick competent (or Fraser guidelines apply), or
Both parents agree, and the treating clinician and multidisciplinary team agree the treatment is in the young person’s best interest

Court authorisation is still required for Stage 3 (irreversible surgery) in most cases and when parents disagree. GPs should advise families that specialist gender services navigate the legal requirements as part of their clinical process.

Privacy and records

Under Australian privacy law, gender identity is sensitive personal information. Patients have the right to have their medical records updated to reflect their gender and preferred name. Take care when generating referral letters, recall systems, or health summaries that might inadvertently disclose a patient’s trans status.

D. Australian operations — prescribing and resources

Gender-affirming hormone therapy in adults

GPs can initiate and monitor gender-affirming HRT in adults under an informed consent model. Document:

Capacity assessment and confirmation that consent is informed, voluntary, and free from coercion
Discussion of effects (reversible and irreversible), timelines, fertility implications, surgical relevance
Baseline investigations and monitoring plan

Masculinising HRT (trans men and transmasculine people — testosterone):

Testosterone (various formulations: Reandron 1000 mg/4 mL IM injection; Testogel/AndroForte transdermal gel; testosterone cream from compounding pharmacies)
Testosterone undecanoate (Reandron) is PBS-listed for male hypogonadism — use may be off-label for gender-affirming purposes; verify current listing
Monitoring: haematocrit (target < 54%), LFTs, lipids, testosterone trough level; cervical screening remains indicated until surgical removal of cervix
Expected effects: voice deepening (irreversible), clitoral growth (variable, largely irreversible), facial and body hair, fat redistribution, cessation of menstruation

Feminising HRT (trans women and transfeminine people — oestradiol ± anti-androgens):

Oestradiol (oral: Progynova; transdermal: Estradot patches, Sandrena gel)
Spironolactone as anti-androgen (PBS-listed for hypertension/oedema; off-label use for anti-androgen purposes)
Cyproterone acetate (Androcur) — very effective but carries small risk of meningioma with prolonged high-dose use; TGA has updated prescribing information; use lowest effective dose
Monitoring: oestradiol and testosterone levels, electrolytes (for spironolactone), LFTs, VTE surveillance; prostate-specific antigen remains relevant if prostate tissue is present

MBS items relevant to gender-affirming care

Consultations are rebated under standard GP MBS items (23, 36, 36C, 44 etc.). There are no specific gender-dysphoria MBS items in general practice. Psychological treatments under the MHCP/MHTP pathway (item 2715) can be accessed for co-occurring mental health conditions.

Key referral contacts

Service	Role
RCH Melbourne Gender Service	Paediatric / adolescent specialist assessment
Sydney Children’s Hospital Gender Service	Paediatric / adolescent specialist assessment
Monash Gender Clinic	Adult specialist care
Northside Clinic (Melbourne)	Adult GP-led affirming care
QLife — 1800 184 527	National counselling/referral for LGBTIQ+ people (3pm–midnight daily)
Transgender Victoria	Community resources, practitioner finder
ACON	NSW-based LGBTIQ+ health organisation

E. Special populations

Children (pre-pubescent)

In pre-pubescent children, gender-diverse expression (toys, clothing, play preferences) is common and does not reliably predict adult gender identity. Clinical intervention is not warranted in pre-pubescent children beyond social affirmation and support. Referral to child-experienced clinicians is appropriate when distress is significant or parents need guidance. Watchful support — not correction — is the affirming approach.

Intersex variations (differences of sex development)

Intersex conditions (differences of sex development — DSD) are distinct from gender dysphoria. People born with DSD may or may not experience gender dysphoria. The two must not be conflated clinically or socially. Irreversible genital surgery on intersex infants who cannot consent remains deeply contested ethically; refer families to specialist DSD teams and the Intersex Human Rights Australia community organisation.

First Nations trans and gender diverse people

Aboriginal and Torres Strait Islander communities have their own traditions of gender diversity, often described through terms such as brotherboy and sistergirl. These identities carry cultural and community meaning that differs from Western trans frameworks. Affirming care should be culturally safe and should not impose Western identity categories. Work alongside Aboriginal Community Controlled Health Services and cultural liaisons.

Older adults

Older trans people may have had limited access to affirming care for decades. Long-term cross-sex hormone use requires monitoring for expected age-related health changes. Many older trans adults have significant accumulated minority stress and may require tailored mental health support. Do not assume gender identity is irrelevant in aged care contexts.

When to escalate

Refer to specialist gender services urgently for:

Adolescents requesting puberty blockers or cross-sex hormones — require multidisciplinary team assessment
Significant psychiatric comorbidity that requires stabilisation before or alongside gender-affirming care
Young people at acute suicidal risk — use standard acute mental health pathways (1800 RESPECT, Lifeline 13 11 14, emergency department)
Requests for surgical referral — requires specialist workup and letters of support per WPATH SOC8

Refer to adult specialist gender clinic (non-urgent) for:

Adults seeking surgical options (mastectomy, vaginoplasty, phalloplasty)
Complex HRT scenarios (polycythaemia, hepatic disease, cardiovascular risk)
Need for letters of support for name/gender change on identity documents

Contact QLife (1800 184 527, 3pm–midnight daily) for patients who need LGBTIQ+ affirming counselling or community connection.

If you or someone you know needs crisis support now: Lifeline 13 11 14 (24/7) · Beyond Blue 1300 22 4636 · 13YARN (First Nations) 13 92 76 · Trans Lifeline 877-565-8860.

What this article is and is not

This article is educational material for patients, carers, and clinicians. It describes Australian clinical pathways, legal frameworks, and current evidence for gender dysphoria and gender-affirming care. It is not individualised medical advice and does not replace assessment by a qualified clinician familiar with the patient’s circumstances.

Evidence in this field is actively evolving, including debate around puberty blocker outcomes and adolescent care pathways. GPs should use current AusPATH guidance as the primary Australian reference and engage in shared decision-making with patients and families.

AHPRA prohibits testimonials, outcome promises, and claims that any treatment is superior for an individual patient. Nothing in this article implies a specific outcome for any reader. Seek care from a qualified Australian GP or specialist for any health concern.

Sources cited

AusPATH Australian Standards of Care and Treatment Guidelines for Trans and Gender Diverse Children and Adolescents (2022) (AU-specialty)
Coleman E et al. WPATH Standards of Care for the Health of Transgender and Gender Diverse People, Version 8. Int J Transgend Health 2022 (specialty-society)
Strauss P et al. Trans Pathways: mental health experiences and care pathways of trans young people. Telethon Kids Institute 2017 (peer-reviewed)
Warrier V et al. Elevated rates of autism, other neurodevelopmental and psychiatric diagnoses, and autistic traits in transgender and gender-diverse individuals. Nat Commun 2020;11:3959 (peer-reviewed)
Re Kelvin (Family Court of Australia, 2017) (AU-specialty)
RACGP — Providing health care for transgender and gender diverse people (RACGP)
Cass H. Independent Review of Gender Identity Services for Children and Young People. NHS England 2024 (specialty-society)
WHO ICD-11 — Gender incongruence (HA60) (specialty-society)
APA DSM-5-TR — Gender Dysphoria (specialty-society)
RCH Melbourne — Gender Service (AU-specialty)
Transgender Victoria — community resources and practitioner finder (AU-consumer)
QLife — national LGBTIQ+ counselling and referral 1800 184 527 (AU-consumer)
TGA — Cyproterone acetate prescribing information update (AU-specialty)

Frequently asked questions

What is the difference between gender dysphoria and gender incongruence?

Gender dysphoria (DSM-5-TR) and gender incongruence (ICD-11) both describe a mismatch between a person's experienced gender identity and their sex assigned at birth, but they differ in framing. DSM-5-TR retains a distress criterion: gender dysphoria requires clinically significant distress or functional impairment as part of the diagnosis. ICD-11's 'gender incongruence' (HA60) does not require distress — it recognises that gender incongruence itself is not inherently pathological, and that distress arises mainly from social stigma and minority stress rather than from gender diversity per se. ICD-11 places gender incongruence in the 'Conditions related to sexual health' chapter, not the mental disorders chapter. Many people with a trans or non-binary gender identity do not meet DSM criteria for gender dysphoria, particularly after social transition.
Can a GP prescribe gender-affirming hormones, or do I need to see a specialist?

In Australia, GPs can prescribe gender-affirming hormone therapy for adults under an informed consent model, consistent with AusPATH 2022 Standards of Care. This means the GP documents the patient's understanding of risks, benefits, alternatives, and the irreversible effects of hormones, and prescribes without requiring a psychiatric gatekeeping letter. Many GPs, particularly in cities, now offer this. For adolescents, the picture is more complex: puberty blockers and cross-sex hormones in adolescents are prescribed by paediatricians or paediatric endocrinologists in consultation with a multidisciplinary team; the Re Kelvin 2017 Family Court ruling means court authorisation is no longer required when both parents and the clinical team agree the treatment is in the young person's best interest.
Are conversion practices legal in Australia?

No — conversion practices targeting sexual orientation or gender identity are banned by law in Victoria, Queensland, the Australian Capital Territory, and New South Wales. The specific legislation and definitions vary between jurisdictions. Practices range from formal 'therapy' programmes to informal pressure from family members or religious leaders. These laws apply to health practitioners, religious practitioners, and parents. The Australian Psychological Society and all major Australian health professional bodies have condemned conversion practices as harmful and ineffective. If a patient discloses they have been subjected to conversion practices, document this as a safeguarding and mental health concern and refer to LGBTQ+ affirming mental health services.
What mental health risks do transgender people face and how does GP care help?

Research — including the Trans Pathways 2017 study of 859 young trans Australians — documents very high rates of psychological distress, with 79.7% reporting self-harm and 48.1% attempting suicide in their lifetime. These rates are overwhelmingly driven by minority stress: discrimination, family rejection, bullying, and lack of affirming care — not by gender identity itself. Gender-affirming care, including access to hormone therapy and social affirmation, is associated with substantial reductions in depression, anxiety, and suicidality. A GP's role in creating an affirming clinical environment — using correct names and pronouns, maintaining confidentiality, conducting sensitive physical assessments — is itself a health intervention. Refer to LGBTQ+ affirming mental health support when psychological distress is present.
What is the evidence around puberty blockers for adolescents in Australia?

Puberty blockers (gonadotropin-releasing hormone analogues such as leuprorelin) are used in Australia to pause endogenous puberty in gender-diverse adolescents during a period of exploration and multidisciplinary assessment. AusPATH 2022 supports their use in appropriate adolescents. The evidence base was reviewed in the UK Cass Report (2024), which raised concerns about the quality of existing studies and prompted NHS England to restrict puberty blocker prescribing outside clinical trials. This finding has been contested by WPATH, EPATH, and many professional bodies who argue the Cass Review applied different evidentiary standards to gender medicine than to comparable paediatric care. Australian guidelines have not adopted the Cass restrictions; access is through paediatric multidisciplinary teams at specialist centres including the Royal Children's Hospital Melbourne and Sydney Children's Hospital. Families and young people should discuss the current evidence and uncertainties openly with their treating team.

Source quality

Sources grouped by evidence tier. AU primary tier first; international where AU is silent or lagging; named-author reconstruction where guidelines have not yet caught up. How tiers work.